-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Financial App News, Hehuang Pharmaceutical (00013.HK) announced that AstraZeneca has submitted a new drug marketing application to the US Food and Drug Administration (FDA) for the treatment of a combination of Vorosha® (ORPATHYS®, savolitinib) and TAGRISSO® (TAGRISSO®, osimertinib) to treat patients with MET during or after treatment with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Patients with locally advanced or metastatic non-small cell lung cancer expressed or amplified.

Zhitongcaijing·09/29/2026 00:09:14
Listen to the news
Zhitong Financial App News, Hehuang Pharmaceutical (00013.HK) announced that AstraZeneca has submitted a new drug marketing application to the US Food and Drug Administration (FDA) for the treatment of a combination of Vorosha® (ORPATHYS®, savolitinib) and TAGRISSO® (TAGRISSO®, osimertinib) to treat patients with MET during or after treatment with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Patients with locally advanced or metastatic non-small cell lung cancer expressed or amplified.